GMAB News and Press, Genmab A/S

2024-07-19 10:20:00 ET Summary In this inflationary environment, we have consistently made adjustments to focus on assets that we consider are capable of maintaining pricing power or are more attractively valued. In the second quarter of 2024, the Baird Chautauqua International Gr...

2024-07-17 07:16:11 ET More on Johnson & Johnson Johnson & Johnson Q2 Earnings Preview: Scrutinizing Its Earnings Quality Johnson & Johnson: Remaining A Buy Despite Remaining Risks Johnson & Johnson: A Lot Of Moving Parts, But Perhaps Finally Lurching...

2024-07-15 17:08:59 ET More on Genmab AbbVie, Genmab blood cancer therapy endorsed in EU Genmab, AbbVie win FDA nod for relapsed follicular lymphoma therapy Genmab A/S (GMAB) Q1 2024 Earnings Call Transcript Read the full article on Seeking Alpha For ...

A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 78.0% to $0.58749 on volume of 130,454,575 shares Ocean Power Technologies Inc. (OPTT) rose 29.6% to $0.2073 on volume of 51,927,154 shares Cosmos Health Inc. (COSM) rose 64.9% to $1.12 on volume of...

2024-06-28 09:29:56 ET More on AbbVie, Genmab, etc. AbbVie: 5 Reasons That Make A Buy Case AbbVie, Inc. (ABBV) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) AbbVie: Turnaround Lurking After The Correction Pain (Upgrade) AbbVie buys bowel...

Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE ® NHL-1 study FL is the second most common type of NHL and accounts for approximately 20-30 percent of all global cases If approved, epcoritamab (TEPKINLY ® ...

2024-06-27 09:00:08 ET Kaveri Pohlman from BTIG issued a price target of $47.00 for GMAB on 2024-06-27 07:34:00. The adjusted price target was set to $47.00. At the time of the announcement, GMAB was trading at $25.67. The overall price target consensus is at $41.80 with...

2024-06-27 08:15:04 ET BTIG analyst issues BUY recommendation for GMAB on June 27, 2024 07:34AM ET. The previous analyst recommendation was Buy. GMAB was trading at $25.67 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst re...

2024-06-27 05:34:44 ET Genmab ( GMAB ) and partner AbbVie ( NYSE: ABBV ) have received U.S. FDA approval for their monoclonal antibody Epkinly (epcoritamab-bysp) for the treatment of adults with relapsed or refractory follicular lymphoma.... Read the full article ...

Company Announcement Approval based on results from Phase 1/2 EPCORE ® NHL-1 study, which demonstrated durable, clinically meaningful treatment responses in patients with challenging-to-treat R/R FL EPKINLY offers an off-the-shelf, T-cell engaging treatment option that ...